Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic
Amount Raised
$95 Million
Round Type
Series C
New YorkOtherBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Ajax Therapeutics, Inc. announced the closing of an oversubscribed $95 million Series C financing. The proceeds will be used to support the clinical development of Ajax’s first-in-class Type II JAK2 inhibitor, AJ1‑11095, for the treatment of myelofibrosis, as well as advancing the company’s pipeline of treatments for MPNs.
Quick answer
Ajax Therapeutics, Inc. raised $95 Million in a Series C round, dated May 13, 2024. Investors: Inning One Ventures, Schrödinger, Boxer Capital, Eco R1 Capital, Point72, RA Capital Management, Vivo Capital and Eli Lilly And Company. Ajax Therapeutics, Inc. is based in New York, New York, United States.
- How much did Ajax Therapeutics, Inc. raise?
- Ajax Therapeutics, Inc. raised $95 Million in a Series C round on May 13, 2024.
- Who invested in Ajax Therapeutics, Inc?
- Inning One Ventures, Schrödinger, Boxer Capital, Eco R1 Capital, Point72, RA Capital Management, Vivo Capital and Eli Lilly And Company are named as investors in this round.
- What does Ajax Therapeutics, Inc. do?
- Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel next generation therapies for myeloproliferative neoplasms (MPNs), including myelofibrosis.
- Where is Ajax Therapeutics, Inc. based and how big is it?
- Ajax Therapeutics, Inc. is based in New York, New York, United States.
- Who are the decision-makers at Ajax Therapeutics, Inc?
- Fundz holds 1 contact at Ajax Therapeutics, Inc., including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Ajax Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.
- CASI Pharmaceuticals raised $15M (Post-IPO Equity) on June 26, 2024.
- CASI Pharmaceuticals raised $15M on June 26, 2024.
- TORL BioTherapeutics raised $158M (Series B) on April 10, 2024.
- TORL BioTherapeutics raised $158M on April 4, 2024.
- DiaMedica Therapeutics raised $12M (Post-IPO Equity) on June 26, 2024.
- Summit Therapeutics raised $200M on June 3, 2024.
Who to call at Ajax Therapeutics, Inc., and when
A new round usually means Ajax Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Ajax Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ajax Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ajax Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ajax Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Ajax Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.